HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Bestrabacil: a possible target-oriented anticancer agent].

Abstract
Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, was initially developed as a target-oriented anticancer agent for breast cancers with positive estrogen receptors, by conjugating a tumoricidal agent, chlorambucil, to a vehicle, estradiol. Further studies, however, revealed that regardless of the presence of estrogen receptors, bestrabucil selectively accumulates in malignant tumor cells. The unique feature of bestrabucil, selective affinity to tumor cells, was demonstrated in in vitro and in vivo studies. Significantly larger amounts of 3H-bestrabucil accumulated in malignant cells (3T3-SV40 transformed) than in normal cells (3T3). In vitro inhibition effects of bestrabucil on cell growth was observed only in malignant cells. Selective accumulation of bestrabucil in malignant tumor tissues was also demonstrated in in vivo experiments. After a single oral administration of 100 mg/kg of bestrabucil to female Wistar rats bearing Walker 256 carcinoma, bestrabucil accumulated significantly occurred in tumor tissues with little or no accumulation in normal tissues and blood. Anti-tumor effects and toxicities of bestrabucil and chlorambucil, were compared using Walker 256 carcinoma. Bestrabucil exerted its antitumor effects with little change in leucocyte counts in the peripheral blood, whereas chlorambucil showed significant side effects. Finally, selective accumulation of bestrabucil in malignant tumor tissues, was demonstrated clinically. Tumor specimens obtained during the operation of patients with various types of cancer, 24 hours after oral administration of 100 mg of bestrabucil, contained significantly larger amounts of bestrabucil compared with adjacent normal tissues. Clinical trials of bestrabucil are being carried out at present. Bestrabucil seems to be a promising target-oriented anticancer agent and deserves further investigation.
AuthorsN Ohsawa, Z Yamazaki, T Wagatsuma, K Isurugi
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 11 Issue 10 Pg. 2115-24 (Oct 1984) ISSN: 0385-0684 [Print] Japan
PMID6548354 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Chlorambucil
  • Estradiol
  • bestrabucil
Topics
  • Administration, Oral
  • Aged
  • Animals
  • Antineoplastic Agents
  • Breast Neoplasms (drug therapy)
  • Cell Division (drug effects)
  • Chlorambucil (analogs & derivatives, blood, metabolism, therapeutic use)
  • Estradiol (analogs & derivatives, metabolism, therapeutic use)
  • Female
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Neoplasms (drug therapy, pathology)
  • Prostatic Neoplasms (drug therapy)
  • Rats
  • Rats, Inbred Strains

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: